Introduction
Rhodiola rosea, also known as the golden root, is one of the most widely studied adaptogenic plants for its ability to enhance physical and mental resilience, improve cognitive performance, and support cellular energy metabolism. Traditionally used in Nordic and Asian herbal medicine, it has become a leading ingredient in the nutraceutical sector, supported by growing clinical evidence confirming its efficacy in reducing fatigue, stress, oxidative imbalance, and mental exhaustion.
Its main bioactive compounds, rosavins and salidroside, act synergistically to regulate the body’s neuroendocrine response to stress and optimize mitochondrial energy release.
Properties and Applications
Rhodiola rosea is a multifunctional ingredient with well-established uses and emerging opportunities:
- Energy and cognitive support: improves focus, memory, and mental endurance while promoting faster recovery from physical and mental fatigue.
• Stress management and mood balance: helps modulate cortisol and serotonin levels, supporting emotional stability and resilience.
• Metabolic balance: recent research indicates potential benefits in improving insulin sensitivity and counteracting oxidative stress.
• Emerging applications: ongoing studies suggest promising roles in immune system modulation and sports performance, due to enhanced antioxidant and cellular recovery mechanisms.
Formulation Challenges and Consumer Compliance
Despite its potential, Rhodiola rosea poses several formulation challenges. Its extract has a distinctively bitter and persistent taste, which can reduce consumer compliance—particularly in oral formulations such as stick packs, chewable tablets, or direct powders.
Additionally, the natural variability of rosavins and salidroside content complicates product standardization and reproducibility of effects.
For nutraceutical manufacturers, it is therefore crucial to have access to an ingredient that is easy to dose, stable, and effectively taste-masked, ensuring both sensory appeal and consistent performance over time.
IPS Innovation: Rhodiola Rosea MINIACTIVES® TM
To meet these challenges, the SURACTIVES® division of IPS has developed Rhodiola Rosea MINIACTIVES® TM, an advanced formulation produced using proprietary MINIACTIVES® technology.
This multi-layer microencapsulation system allows:
• Effective taste and odor masking of the natural extract, improving consumer compliance.
• Enhanced stability of sensitive bioactive compounds during storage and processing.
• Precision and uniformity of dosing, thanks to perfectly spherical and regular pellets.
• Improved gastric tolerability, through gradual release of the active compound.
The MINIACTIVES® TM version thus represents a technologically advanced and sensorially refined solution, preserving the full biological efficacy of Rhodiola rosea while optimizing formulation flexibility and user experience.
Scientific Validation and Preclinical Studies
The SURACTIVES® division of IPS is deeply committed to the scientific validation of its proprietary technologies through in vitro preclinical studies performed on human intestinal organoids and advanced 3D cell systems.
These studies—conducted on other active ingredients formulated using MATRIS® and MINIACTIVES® technologies—have demonstrated that improvements in absorption, bioaccessibility, and gastrointestinal safety derive mainly from the coating technology, independent of the active substance itself.
Building on these results, IPS is extending this scientific validation to new proprietary formulations, including Rhodiola Rosea MINIACTIVES® TM, in collaboration with specialized research laboratories.
Formulations and Applications
Thanks to its technological versatility, Rhodiola Rosea MINIACTIVES® TM can be incorporated into a wide range of nutraceutical dosage forms, including:
• Tablets and capsules – for daily use or multi-active formulations;
• Single-dose sachets and stick packs – ideal for functional, ready-to-drink products;
• Vials with dosing caps – for advanced liquid applications;
• SmarTTabs® – specific for direct compression, fully preserving the release profile.
Additionally, IPS offers different concentration options, allowing formulators to tailor the rosavins and salidroside content to precise market and product needs.
Conclusion
Rhodiola Rosea MINIACTIVES® TM represents a next-generation approach to adaptogen formulation, combining proven phytotherapeutic efficacy with enhanced sensory properties and technological precision.
Through continuous innovation and rigorous preclinical validation, the SURACTIVES® division of IPS confirms its commitment to delivering scientifically supported, stable, and technologically advanced ingredients for the nutraceutical industry — designed to improve not only product performance but also consumer experience and compliance.
Note: This article is provided for informational purposes only and does not substitute professional medical advice.
